A novel specific bioassay for the determination of glucocorticoid bioavailability in human serum

objective Some patients develop side‐effects even on relatively low doses of topically administered glucocorticoids (GCs), while others appear to be less sensitive to GCs. We have developed and validated a bioassay which can measure glucocorticoid bioavailability directly from small amounts of human serum to help elucidate underlying mechanisms.

[1]  T. Raivio,et al.  Transactivation assay for determination of glucocorticoid bioactivity in human serum. , 2002, The Journal of clinical endocrinology and metabolism.

[2]  E. Hollander,et al.  Hypothalamic-pituitary-adrenal Axis Dysregulation in Depersonalization Disorder , 2001, Neuropsychopharmacology.

[3]  M. Duclos,et al.  Fat distribution in obese women is associated with subtle alterations of the hypothalamic–pituitary–adrenal axis activity and sensitivity to glucocorticoids , 2001, Clinical endocrinology.

[4]  C. Crim,et al.  A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. , 2001, Clinical therapeutics.

[5]  B. Lipworth,et al.  Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. , 2001, British journal of clinical pharmacology.

[6]  G. Chrousos,et al.  Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes. , 2001, The Journal of endocrinology.

[7]  Carmine M Pariante,et al.  Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment , 2001, Biological Psychiatry.

[8]  J. Toppari,et al.  Adrenocorticotropin and corticotropin-releasing hormone tests in preterm infants. , 2000, The Journal of clinical endocrinology and metabolism.

[9]  Florian Holsboer,et al.  The Corticosteroid Receptor Hypothesis of Depression , 2000, Neuropsychopharmacology.

[10]  E. Moilanen,et al.  Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. , 2000, European journal of pharmacology.

[11]  S. Lamberts,et al.  Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene. , 2000, The Journal of clinical endocrinology and metabolism.

[12]  B. Carroll,et al.  Dexamethasone metabolism in dexamethasone suppression test suppressors and nonsuppressors , 2000, Biological Psychiatry.

[13]  R. Voutilainen,et al.  Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. , 2000, The Journal of clinical endocrinology and metabolism.

[14]  Kelly Hw.  Comparative potency and clinical efficacy of inhaled corticosteroids. , 1999 .

[15]  C. Dayan,et al.  Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. , 1999, The Journal of clinical endocrinology and metabolism.

[16]  J. Grice,et al.  Comparison of adrenocorticotropin (ACTH) stimulation tests and insulin hypoglycemia in normal humans: low dose, standard high dose, and 8-hour ACTH-(1-24) infusion tests. , 1999, The Journal of clinical endocrinology and metabolism.

[17]  B. Lipworth,et al.  Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate , 1999, Thorax.

[18]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[19]  B. Walker,et al.  Glucocorticoids and insulin resistance: old hormones, new targets. , 1999, Clinical science.

[20]  J. Planquois,et al.  A comparison of the inhibitory effects of budesonide, beclomethasone dipropionate, dexamethasone, hydrocortisone and tixocortol pivalate on cytokine release from leukocytes recovered from human bronchoalveolar lavage , 1999, Inflammation Research.

[21]  A D Vethaak,et al.  Development of a stably transfected estrogen receptor-mediated luciferase reporter gene assay in the human T47D breast cancer cell line. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  W. Oelkers,et al.  Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. , 1998, The Journal of clinical endocrinology and metabolism.

[23]  H. Pols,et al.  Bone mineral density and bone metabolism of prepubertal children with asthma after long‐term treatment with inhaled corticosteroids , 1997, Pediatric pulmonology.

[24]  H. Derendorf.  Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. , 1997, Respiratory medicine.

[25]  R. Cooke,et al.  Inhaled beclomethasone dipropionate suppresses the hypothalamo–pituitary–adrenal axis in a dose dependent manner , 1997, Clinical endocrinology.

[26]  D. Cutler,et al.  Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects , 1997, Biological Psychiatry.

[27]  P. Laippala,et al.  Growth of asthmatic children is slower during than before treatment with inhaled glucocorticoids , 1997, Acta paediatrica.

[28]  M. Brönnegård,et al.  Steroid receptor number. Individual variation and downregulation by treatment. , 1996, American journal of respiratory and critical care medicine.

[29]  S. Lamberts,et al.  Clinical aspects of glucocorticoid sensitivity , 1996, Steroids.

[30]  P. Mulatero,et al.  Inhibition of lysozyme synthesis by dexamethasone in human mononuclear leukocytes: an index of glucocorticoid sensitivity. , 1994, The Journal of clinical endocrinology and metabolism.

[31]  F. Holsboer,et al.  The plasma dexamethasone variable in depression: Test- retest studies and early biophase kinetics , 1986, Psychiatry Research.

[32]  J. Dunn,et al.  Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. , 1981, The Journal of clinical endocrinology and metabolism.

[33]  G. Levy,et al.  Serum protein binding of drugs during and after pregnancy in humans , 1980, Clinical pharmacology and therapeutics.

[34]  Bart van der Burg,et al.  Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. , 2003, The Journal of clinical endocrinology and metabolism.

[35]  D. Grobbee,et al.  A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. , 1998, The Journal of clinical endocrinology and metabolism.

[36]  M. Johnson,et al.  Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. , 1996, The Journal of allergy and clinical immunology.